ENFORCED TUMOR SPECIFIC MHC-I HETEROGENEITY IN TRIPLE NEGATIVE BREAST CANCER DRIVES IMMUNOTHERAPY RESISTANCE

被引：2
|
作者：
Taylor, Brandie [1 ]
Balko, Justin [2 ]
Sanders, Melinda [2 ]
Gonzalez-Ericsson, Paula [2 ]
Sanchez, Violeta [2 ]
机构：
[1] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.318
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
318
引用
收藏
页码：A342 / A342
页数：1
相关论文
共 50 条
  • [31] Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression
    Yang, Yun-Song
    Jin, Xi
    Li, Qin
    Chen, Yi-Yu
    Chen, Fenfang
    Zhang, Hena
    Su, Ying
    Xiao, Yi
    Di, Gen-Hong
    Jiang, Yi-Zhou
    Huang, Shenglin
    Shao, Zhi-Ming
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (46)
  • [32] Ferroptosis Heterogeneity in Triple-Negative Breast Cancer Reveals an Innovative Immunotherapy Combination Strategy
    Yang, Fan
    Xiao, Yi
    Ding, Jia-Han
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    CANCER RESEARCH, 2023, 83 (05)
  • [33] Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy
    Yang, Fan
    Xiao, Yi
    Ding, Jia-Han
    Jin, Xi
    Ma, Ding
    Li, Da-Qian
    Shi, Jin-Xiu
    Huang, Wei
    Wang, Yi-Pin
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    CELL METABOLISM, 2022, 35 (01) : 84 - 100
  • [34] Both MHC I and MHC II Pathways Are Associated with Improved Survival in Triple-Negative Breast Cancer
    Iqbal, Jabed
    Yeong, Joe
    Lee, Bernett
    Lim, Jeffrey C. T.
    Cheng, Xin Min
    Tan, Puay Hoon
    MODERN PATHOLOGY, 2017, 30 : 458A - 458A
  • [35] Both MHC I and MHC II Pathways Are Associated with Improved Survival in Triple-Negative Breast Cancer
    Iqbal, Jabed
    Yeong, Joe
    Lee, Bernett
    Lim, Jeffrey C. T.
    Cheng, Xin Min
    Tan, Puay Hoon
    LABORATORY INVESTIGATION, 2017, 97 : 458A - 458A
  • [36] Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer
    Schreier, Ashley
    Zappasodi, Roberta
    Serganova, Inna
    Brown, Kristy A.
    Demaria, Sandra
    Andreopoulou, Eleni
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [37] MHC CLASS I LASER IMMUNOTHERAPY FOR BREAST CANCER
    DeVette, Christa
    Hoover, Ashley
    Chen, Wei
    Hildebrand, William H.
    HUMAN IMMUNOLOGY, 2019, 80 : 126 - 126
  • [38] Spatial transcriptomics delineates tumor heterogeneity in NACT triple-negative breast cancer
    Wall, Isobelle
    Quist, Jelmar
    Pinder, Sarah
    Irshad, Sheeba
    Gillet, Cheryl
    Seewaldt, Victoria
    Mukund, Kavitha
    Frankhouser, David
    Subramaniam, Shankar
    Parsons, Maddy
    Grigoriadis, Anita
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
    Bai, Xupeng
    Ni, Jie
    Beretov, Julia
    Graham, Peter
    Li, Yong
    JOURNAL OF THE NATIONAL CANCER CENTER, 2021, 1 (03): : 75 - 87
  • [40] Sensitization to carboplatin chemotherapy by decoding intra tumor heterogeneity in triple negative breast cancer
    Chowdhury, S. Roy
    Kravchenko-Balasha, N.
    Rubinstein, A.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S146 - S147
12345